weekly_roundup

BioTechSign Daily Catalyst Roundup - November 15, 2026

Top BioTechSign catalyst names today: YMAB, EYPT, SRPT, SMMT, IBRX, IDYA. FDA, clinical trial, grade-change, dilution, and sentiment signals.

BiotechSign AnalysisNovember 15, 2026

Daily Biotech Catalyst Digest: November 15, 2026

YMAB leads the current BioTechSign screen at 98.3/100 with a grade of A. The daily view combines FDA timing, clinical activity, publications, dilution risk, short interest, institutional/fund flow, and market-sentiment convergence into one research queue.

Top Catalyst Scores

TickerCompanyScoreGradeStrongest Inputs
YMABY-mAbs Therapeutics98.3Aclinical activity 100%, publication signal 15%
EYPTEyePoint, Inc.84.2Aclinical activity 100%, short interest 70%, dilution risk 43%
SRPTSarepta Therapeutics84.2Apublication signal 100%, clinical activity 96%, short interest 70%
SMMTSummit Therapeutics Inc.82.7Apublication signal 100%, clinical activity 100%, short interest 90%
IBRXImmunityBio, Inc.80.7Apublication signal 100%, clinical activity 100%, short interest 90%
IDYAIDEAYA Biosciences79.7Bpublication signal 100%, clinical activity 100%, short interest 50%

Recent Grade-Change Queue

  • SMMT (Summit Therapeutics Inc.) currently grades A with a 82.7/100 catalyst score. Main inputs: publication signal 100%, clinical activity 100%, short interest 90%.
  • IBRX (ImmunityBio, Inc.) currently grades A with a 80.7/100 catalyst score. Main inputs: publication signal 100%, clinical activity 100%, short interest 90%.
  • VRTX (Vertex Pharmaceuticals) currently grades B with a 67.1/100 catalyst score. Main inputs: publication signal 100%, clinical activity 100%, PDUFA timing 90%.
  • NVO (Novo Nordisk) currently grades B with a 73.3/100 catalyst score. Main inputs: publication signal 100%, clinical activity 100%, dilution risk 12%.
  • BNTX (BioNTech SE) currently grades B with a 74.0/100 catalyst score. Main inputs: publication signal 100%, clinical activity 100%, dilution risk 15%.
  • BMRN (BioMarin Pharmaceutical) currently grades B with a 74.5/100 catalyst score. Main inputs: publication signal 100%, clinical activity 100%, short interest 30%.
  • TGTX (TG Therapeutics) currently grades B with a 77.7/100 catalyst score. Main inputs: clinical activity 100%, short interest 70%, dilution risk 11%.
  • AZN (AstraZeneca) currently grades C with a 52.0/100 catalyst score. Main inputs: publication signal 100%, clinical activity 100%, dilution risk 12%.

What To Watch

Names with high clinical-trial and publication inputs deserve a pipeline read-through. Names with elevated dilution or short-interest inputs deserve tighter risk review before any catalyst trade. The purpose of this feed is to surface candidates for research, not to make buy or sell recommendations.